tage of TACE is that it has been shown to be a safe technique in high-risk patients. Multiple studies have shown that TACE provides symptomatic control in patients with neuroendocrine metastases [5] .
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and December 2007 were retrospectively evaluated. Approval for this study was obtained from the institutional review board, and informed consent was obtained from all patients. Patient consent included approval of the protocol of treatment and the anonymous use of the results in a research study.
The current study included 48 patients (age range, 37-77 years; mean age, 61.1 years; SD, 10.3). The inclusion criteria were patients with a liver metastasis or metastases from neuroendocrine tumors, patients without extrahepatic metastases, and those who did not receive concomitant systemic chemotherapy or hormonal therapy. Before intervention, the therapeutic indications were symptomatic treatment in nine patients (18.75%) and palliative therapy in 39 patients (81.25%). Palliative therapy was defined as therapy for asymp tomatic patients intended mainly to prolong survival and to preserve and improve quality of life without curing the disease. Symptomatic treatment was defined as a therapy intended to alleviate or decrease tumor-related symptoms (e.g., pain, bulk-related symptoms). The protocol of management was based on the recommendations and government of the institutional oncology board, which includes medical oncologists.
Patient demographics, lesion pathology, treatment, and outcome data, including all histopathology reports and imaging studies, were collected from the electronic medical record archiving system and were subsequently analyzed. In all patients, the diagnosis was made by staff pathologists from our institute based on histologic and immunohistochemical examinations of pathologic specimens. The primary tumor was the source of the biopsy material. For metastases of unknown origin, liver metastases were the source of biopsy material as part of the investigation workup to define the primary cancer.
Information concerning disease-related symptoms, laboratory values, surgical method performed, and adjuvant treatment techniques were obtained from patient reports. Special emphasis was placed on the stage of disease at the time of first embolization: The number of liver tumors and the location and diameter of the largest liver tumor were obtained by reevaluating the original CT and MRI scans. Contraindications to the therapeutic protocol of the study included poor performance status (Karnovsky status ≤ 70%), nutritional impairment, presence of ascites, high serum total bilirubin level (> 3 mg/dL [51.3 µmol/L]), poor hepatic synthesis (serum albumin level < 2.0 mg/dL [20 g/L]), and renal failure (serum creatinine level > 2 mg/dL [176.8 µmol/L]). Partial or complete thrombosis of the main portal vein was a further exclusion criterion for the procedure in addition to cardiovascular or respiratory failure. To ensure adequate treatment compliance, patients were required to have a sound mental state to provide legitimate consent. Nutritional assessment was carried out using the scored patient-generated subjective global assessment, which is one of the standard methods used in many centers for assessing nutritional status in oncology patients [6, 7] .
Patients were classified according to the chemotherapeutic drug protocol used in group 1 or group 2. For group 1, mitomycin C was used between January 1996 and December 2001, and for group 2, both mitomycin C and gemcitabine were used between January 2002 and December 2007. The change in the management protocol was based on the recommendations and government of the institutional oncology board, which includes medical oncologists. 
Two Transarterial Chemotherapy Protocols for Liver Metastases
Patients included in the study had been referred from oncologists, and the TACE procedure was performed in our center on an outpatient basis. However, the usual practice is to use blocking agents in endocrine-active tumors and hospitalize patients to guard against postembolization hormonal crisis. Observation is performed for 10-12 hours after the procedure including ensuring adequate hydration and symptomatic treatment of pain and vomiting. After the observation time, patients who had remained symptom-free were discharged to the care of the referring oncologist. If complications developed, patients were to be readmitted immediately. The procedure was technically successful and was tolerated by all patients.
Data of Group 1 Patients
Group 1 included 18 patients, 13 men and five women, ranging in age from 42 to 74 years with a mean age of 61.1 years (SD, 10.6). The primary neuroendocrine tumors were as follows: 12 intestinal tumors, two pulmonary tumors, two pancreatic endocrine tumors, and two adrenal tumors. Five patients had one metastasis, two patients had two metastases, two patients had three metastases, and nine patients had multiple metastases (≥ 5 metastases). The patients underwent 182 therapeutic sessions (range, 6-24 sessions; mean, 10.11 sessions; SD, 5.95) using mitomycin C, a chemotherapy drug. The indications for therapy were symptomatic treatment in three patients (16.67%) and palliative treatment in 15 patients (83.33%). Symptoms were either local caused by tumor bulk (right hypochondrial pain or abdominal mass) in or in the form of gastrointestinal tract manifestations including persistent nausea, vomiting, loss of weight, and diarrhea (Tables 1-3) .
Data of Group 2 Patients
Group 2 included 30 patients, 18 men and 12 women, ranging in age from 37 to 77 years with a mean age of 59.3 years (SD, 9.7). The primary neuroendocrine tumors were as follows: 15 smallbowel tumors, two pulmonary tumors, nine pancreatic tumors, and four colonic tumors. Eight patients had one metastasis, one patient had three metastases, and 21 patients had multiple metastases (≥ 5 metastases). The patients underwent 312 therapeutic sessions (range, 3-24 sessions; mean, 10.4 sessions; SD, 5.91) using mitomycin C and gemcitabine chemotherapy drugs. The indications for therapy were symptomatic treatment in six patients (20%) and palliative treatment in 24 patients (80%) ( Tables 1 and 2) .
Resection of the primary tumor was performed in 13 of 18 patients (72.2%) in group 1 and 19 of 30 patients (63.3%) in group 2. All patients in both groups received systemic chemotherapy before chemoembolization. Once the treatment of chemoembolization had been established, no one received adjuvant systemic chemotherapy.
Therapeutic Protocol for Patients
The therapeutic procedures were performed by the same interventionist who had more than 18 years' experience in the field of interventional radiology at the time of the study. After the introduction of a selective catheter through the femoral artery using the Seldinger technique, the localization of the hepatic arteries was confirmed via celiac and mesenteric arteriography using selective catheterization to define the vascular anatomy [8] . Indirect portography was next performed to outline the portal circulation in the venous phase. Subsequently a catheter was placed in the celiac trunk and advanced beyond the gastroduodenal artery. Depending on the size of the tumor, location of the tumor, and arterial supply to the tumor, the tip of the catheter was advanced further into the segmental arteries. The chemotherapeutic agent consisted of mitomycin C alone (8 mg/m 2 ; mitomycin C, Medac GmbH) for group 1 patients and the combination of mitomycin C (8 mg/m 2 ) with gemcita bine (1,200 mg/m 2 ; Gemzar, Lilly Pharma) for group 2 given sequentially and followed by injection of the embolizing materials slowly under fluoroscopic control until stasis of blood flow was observed. Vogl et al.
The embolization was performed with a maximum of 15 mL/m 2 of iodized oil (Lipiodol), followed by an injection of 200-450 mg of degradable starch microspheres (EmboCept, PharmaCept) for vessel occlusion. The embolization material was injected slowly with fluoroscopic control until stasis of blood flow was observed. After embolization, devascularization was confirmed with additional angiography of the hepatic arteries. This study was designed to include the performance of at least three sessions of repeated transarterial chemotherapy and embolization, with a treatment interval of 4 weeks. For patients with bilobar disease, the treatment was performed to control disease in the lobe with higher tumor burden as seen on MRI performed immediately before the procedure; the second lobe was treated in another session. The treatment was directed selectively toward the largest lesions (1-3 lesions per session). The patients were carefully observed after hepatic artery chemotherapy and embolization, and symptoms of postembolization syndrome were treated. The end point of chemotherapy and embolization treatment was defined as stable disease for two successive sessions or disease progression.
Follow-Up and Imaging Analysis
The morphologic tumor response (number, localization, and bulk) was evaluated on MRI in consensus by two senior radiologists with 15 and 8 years' experience. For initial treatment planning, unenhanced and contrast-enhanced MRI was performed. Unenhanced CT was performed 24 hours after embolization to verify that iodized oil had been retained in the tumor and the liver parenchyma, which also reflects the activity of the tumor cells. In addition, CT allows optimal comparison between results on follow-up images in the subsequent sessions and can efficiently exclude major postprocedure complications such as pancreatitis, hepatic infarction, mesenteric ischemia, and ascites or ectopic embolization. CT was performed with the helical technique (section thickness, 8 mm) using CT scanners (Somatom Plus or Somatom Plus 4, Siemens Healthcare). All responses were based on MRI findings. The dimensions of the lesions on follow-up and comparison of those dimensions with the control study dimensions were assessed using MRI owing to its high sensitivity and the high resolution of the images provided.
The volume of the target metastases was measured using transverse imaging to evaluate the longest cross-sectional diameter as the length and the perpendicular diameter as the width. Tumor volume was calculated on the basis of the evaluated diameters on transverse images with the following ellipsoidal volume equation:
where l refers to the length of the tumor; w, the width; and h, the height. The change in size was calculated by radiologic evaluation using MRI. The response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was defined as the complete disappearance of all recognizable tumor in the liver confirmed at 4 weeks after the procedure. Partial response was defined as a reduction of at least 30% in the sum of the longest diameter of the target lesions, taking as reference the baseline study, and was confirmed at 4 weeks. Stable disease was defined when neither partial response nor progressive disease criteria were met, taking as reference the smallest sum of the longest diameter recorded since treatment started. Progressive disease was defined as the appearance of new lesions or as an increase of at least 20% in the sum of the longest diameter of the target lesions, taking as reference the smallest-sum longest diameter recorded since treatment started [9] . Survival times were calculated beginning with the dates of the first TACE treatment and the date of diagnosis of liver metastases using the Kaplan-Meier method [10] . The log-rank test (Cox-Mantel's χ 2 value) was used to determine the significance of the difference between patient survival rates in the two chemotherapy protocol groups. A p value of < 0.05 was considered to be statistically significant.
Results

Technical Details of the Protocol of Treatment, Tolerance, and Side Effects
A dose of 8 mg/m 2 of mitomycin C was given to both groups, whereas a dose of 1,200 mg/ m 2 of gemcitabine was given only to group 2. Chemotherapy was given sequentially and was followed by slow injection of embolizing materials under fluoroscopic control until stasis of the blood flow was observed. Embolization was performed with a maximum of 15 mL/m 2 of Lipiodol and was followed by injection of 200-450 mg of EmboCept for vessel occlusion.
Both treatment protocols were well tolerated by all patients, with only minor side effects in both groups and no major complications occurring. Symptomatic improvement was recognized starting from the second therapeutic session in both groups, particularly with regard to right hypochondrial pain, nausea, vomiting, and diarrhea, as well as effort tolerance and quality of life.
The side effects observed in group 1 included nausea and vomiting in five of 18 patients 
MRI Findings
Local tumor morphologic evaluations according to RECIST criteria were as follows for group 1 (n = 18): partial response in two patients (11.1%), stable disease in nine patients (50%), and progressive disease in seven patients (38.9%). For group 2 (n = 30), partial response was seen in seven patients (23.3%), stable disease in 16 patients (53.3%), and progressive disease in seven patients (23.3%). Tumor response according to RECIST criteria was compared between gastrointestinal tract tumors versus pancreatic tumors (Tables  3 and 4) .
MRI volumetric response of tumor load to the treatment protocol of both groups revealed progressive reduction of the mean tumor volumes over a 3-month follow-up interval in comparison to the pretherapeutic mean tumor volume in group 1 patients. Comparatively the initial reduction in the mean tumor volume in the first 6 months was followed by progressive increase afterward in group 2. Volumetric results are summarized in Table 4 . However, the mean volumetric changes between pre-and posttreatment tumor volumes were not statistically significant for group 1 or group 2, with a p value of 0.09 and 0.06, respectively (Table  3 and Fig. 1 ).
Correlation Between Tumor Response and Iodized Oil Uptake on Unenhanced CT
In both groups, metastases with heterogeneous Lipiodol uptake tended to progress more frequently (60%; p = 0.04) than those with homogeneous uptake (24%; p = 0.1) in which metastases revealed stable disease and partial response.
Survival Analysis and Extrahepatic Progression
The survival rates, which were calculated from the time of first diagnosis, from the first year until the fifth year in group 1 were as the follows: 94.4% in the first year, 77.78% in the second year, 72% in the third year, 22.2% in the fourth year, and 11.1% in the fifth year. The survival rates in group 2 were 100% in the first year, 90% in the second year, 80% in the third year, 63.3% in the fourth year, and 46.7% in the fifth year (Table 3 , Figs. 2 and 3) .
The median survival time of group 1 starting from the first diagnosis was 38.7 months, (range, 10-68 months), whereas the median survival time of the same group starting from the first transarterial chemotherapy session was 32.9 months (range, 5-56 months). In group 2 the median survival time starting from the first diagnosis was 57.1 months (range, 14-98 months), and the median survival time starting from the first TACE session was 42.8 months (range, 10-72 months). The time lapse between the diagnosis and first treatment of group 1 was 5-9 months and for group 2, 4-12 months. A significant difference in the survival rates, which were calculated from the date of first diagnosis and first TACE session of both patient groups, was detected for both groups on analysis by log-rank test (Cox-Mantel's χ 2 method), with a p value of 0.001 and 0.005, respectively.
Resection of the primary tumor was performed in 13 of 18 patients (72.2%) in group 1 and 19 of 30 patients (63.3%) in group 2.
The mean time of extrahepatic progression in group 1 was 10.2 months (SD, 2.3), whereas in group 2 the mean progression time was 16.4 months (SD, 4.2).
Discussion
The presence and extension of hepatic metastases are considered to be among the most important prognostic factors for patients with neuroendocrine tumors. These factors significantly impair a patient's quality of life as a result of the symptoms caused by endocrine tumor products. Effective treatment of liver metastases is crucial to maintain optimal palliative treatment of patients with advanced neuroendocrine tumors because only 5% of patients with carcinoid syndrome undergo complete radical liver surgery [11] . Multimodality treatment protocols, including surgery of the primary tumor and metastases, TACE, and adjuvant pharmacologic treatment (bioimmunotherapy and chemotherapy), have been established for the treatment of metastatic gastrointestinal neuroendocrine tumors [12] [13] [14] . Symptomatic patients may benefit from TACE in terms of improved quality of life or reduced dose of somatostatin analog. Radiofrequency ablation has also been applied for the treatment of hepatic metastases resulting from neuroendocrine tumors in many series in the literature [15] [16] [17] [18] .
According to the RECIST criteria of tumor morphologic changes used in both patient groups, there was an improved response in group 2 patients versus group 1 patients regarding tumor regression, tumor course stability, and tumor progression. We attribute these differences in response to the synergistic and cumulative effects of both mitomycin C and gemcitabine on tumor activity. This potentiating effect of the combination of mitomycin C and gemcitabine was also reflected in the median survival time of group 2 patients. The response of gastrointestinal tract tumors was more favorable than that of pancreatic tumors in both groups.
Seldinger [6] reported a median survival time of 24 months in 23 patients after the initial TACE using Adriamycin and Lipiodol. In a study of eight patients with carcinoid tumors, Hajarizadeh et al. [19] reported a mean survival time of 40 months from the initial diagnosis with chemoembolization using a mixture of doxorubicin, cisplatin, mitomycin C, and Lipiodol. In their study of 18 patients with liver metastases from neuroendocrine tumors, Touzios et al. [5] followed up on the results of TACE therapy using a protocol of combined cisplatin, doxorubicin, and mitomycin C. The median and 5-year survival rates were 50 months and 50%, respectively. Ruutiainen et al. [20] used a protocol of cisplatin, doxorubicin, mitomycin C, iodized oil, and polyvinyl alcohol. The survival rates at 1, 3, and 5 years after therapy were 86%, 67%, and 50%, respectively. They also reported that severe toxicity after chemoembolization was seen in 25% of cases, possibly because of the combination of multiple chemotherapeutic agents used simultaneously. Loewe et al. [21] described the effect of permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and Lipiodol on the short-and long-term results. The median survival time reported in that study was 69 months, and the estimated cumulative survival rates reached 95.7% and 65.4% at 1 and 5 years after diagnosis, respectively. Permanent arterial embolization, however, carries a technical disadvantage in that another intervention might not be technically feasible after the permanent embolization of all hepatic arteries. They also reported major complications after this protocol including two deaths (8.7%) that occurred within 1 month of treatment and a vascular complication that occurred at the time of embolization [21] .
In comparison with the data for TACE reported in the literature, the effect on survival rates achieved by the treatment protocols used in this study, particularly that used for group 2 patients, appears to be favorable, although the number of therapeutic sessions needed was relatively higher. This study used only one or two chemotherapeutic agents to strike a balance between the increased synergistic therapeutic effects of the chemotherapeutic agents and minimization of the toxic side effects from the use of multiple therapeutic agents.
In this study, patients with tumors that had heterogeneous Lipiodol uptake on CT had a higher tendency to show progressive disease during the follow-up period than those with tumors that had homogeneous uptake in both groups. These results are in accordance with other results shown by the effect of TACE on other tumors including hepatocellular carcinoma [22] .
A recent study by de Baere et al. [23] emphasized the effect of drug-eluting beads loaded with doxorubicin on progressive liver metastases from well-differentiated gastroenteropancreatic endocrine tumors in 20 patients. Partial response, stable disease, and progressive disease achieved on 3-month follow-up were 80%, 15%, and 5%, respectively. The median time to progression was 15 months. However, complications reported include postembolization syndrome in 67% of the patients and TACE-induced peripheral liver necrosis in 25% [23] .
A limitation of our study is the retrospective study design; however, because of the slow growth and the relatively low incidence rate of neuroendocrine carcinomas, inclusion of a large study population from a single institution of prospective fashion would be difficult. Another limitation is the unequal number of patients in groups 1 and 2.
In conclusion, the dual regimen of gemcitabine and mitomycin C is superior to mitomycin C alone and provides an effective treatment of the hepatic metastases resulting C Fig. 1-46 -year-old woman (patient from group 2) with neuroendocrine carcinoma. A, Axial MRI scan shows metastatic liver lesion (arrow) from undifferentiated colonic neuroendocrine carcinoma. B, Axial MRI scan obtained after first embolization session shows liver uptake of iodized oil (Lipiodol, Guerbet) (arrow). Also note tip of microcatheter in artery is supplying tumor (arrowhead). C, Axial MRI scan obtained after third embolization shows more than 50% reduction in size of tumor (arrow), which is representative of partial response. D, Image obtained after third embolization session shows reduction in tumor uptake of Lipiodol (arrow). Tip of microcatheter can be seen in vessel supplying tumor (arrowhead). Fig. 2-Kaplan-Meier survival curve for both groups from initial diagnosis. Group 1 patients (n = 18) were treated using transarterial chemotherapy with mitomycin C. Median survival rate was 38.67 months (range, 10-68 months). Group 2 patients (n = 30) were treated using transarterial chemotherapy with combination of mitomycin C and gemcitabine. Median survival rate of group 2 was 57.1 months (range, 14-98 months). Fig. 3 -Kaplan-Meier survival curve for both groups from initial therapy. Group 1 patients (n = 18) were treated using transarterial chemotherapy with mitomycin C. Median survival rate was 32.89 months (range, 5-56 months). Group 2 patients (n = 30) were treated using transarterial chemotherapy with combination of mitomycin C and gemcitabine. Median survival rate of group 2 was 42.8 months (range, 10-72 months).
